Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor

2018 ◽  
Vol 103 (6) ◽  
pp. 1020-1028 ◽  
Author(s):  
Ann E. Herman ◽  
Leslie W. Chinn ◽  
Shweta G. Kotwal ◽  
Elaine R. Murray ◽  
Rui Zhao ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Healthy Volunteers ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Bruton's Tyrosine Kinase

scholarly journals Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2808-2810 ◽  
Author(s):  
Harriet S. Walter ◽  
Sandrine Jayne ◽  
Simon A. Rule ◽  
Guillaume Cartron ◽  
Franck Morschhauser ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document